Swot of Indian pharmaceutical industry

by Sunil Nair on Monday 24 May 2010, 2:29 PM | Category: Strategy| View: 1385 views
 
 
Advertisements
 

Swot of Indian pharmaceutical industry

Strengths
·        Cost competitiveness
·        Well developed industry with strong manufacturing base
·        Well established network of laboratories and r&d infrastructure, strong motivated scientific force
·        Self reliant technology for production
·        Access to pool of highly trained scientists
·        Strong marketing and distribution network
·        Rich biodiversity
·        Low r&d costs
·        Competencies in chemistry and process development
·        Cost effective technologies for bulk drugs production and well developed capital equipment industry
·        Increasingly, india is being regarded as a manufacturing base by global pharmaceutical companies.
 
 
Weakness
·        Low investments in innovative r&d.
·        Lack of resources to compete with mncs for new drug discovery research and to commercialize molecules on a worldwide basis.
·        Lack of strong linkages between industry and academia.
·        Lack of culture of innovation in the industry
·        Low medical expenditure and healthcare spend in the country
·        Inadequate regulatory standards
·        Production of spurious and low quality drugs tarnishes the image of industry at home and abroad.
 
Opportunities
·        Significant export potential
·        Licensing deals with mncs for ndds
·        Marketing alliances to sell mnc products in domestic market
·        Contract manufacturing arrangements with mncs
·        Potential for developing india as a centre for international clinical trials
·        Niche player in global pharmaceutical r&d.
·        Strong base of scientific as well as technical manpower and also due to pioneering work done in process development
·        Supply of generic drugs to developed markets
 
 
Threats
·        Product patent regime poses serious challenge to domestic industry unless it invests in research and development.
·        DPCO puts unrealistic ceilings on product prices and profitability and prevents pharmaceutical companies from generating investible surplus
·        R&d efforts of indian pharmaceutical companies hampered by lack of enabling regulatory requirement.
·        Entrants of newer players in highly fragmented market.
 

 

Advertisements
Print-Friendly Version Email to a Friend
 
Related to Swot of Indian pharmaceutical industry
 
 
 
 
 
 
STATS
 
Total articles: 7758
    Total Categories: 22
    Updated in Last Week: 0
LOGIN
 
   Login Id
   Password
  Forgot Password?
    
   
SEARCH ARTICLE
 
  Enter Keywords
 
CATEGORIES
 
    Banking and Finance
    Campus Articles
    Economy
INVITE FRIENDS
 
Invite your Friends, your Colleagues, your Group Members, your Seniors, your Team mates...and others.
 
 
Advertisements


 
spacer gif
Management Paradise
spacer gif
arrow gif About Us
Press
Jobs
MBA Projects
Kartik Raichura
spacer gif
spacer gif
spacer gif
Legal
spacer gif
spacer gif Terms & Conditions
spacer gif Privacy Policy
spacer gif Disclaimer
spacer gif Copyrights
spacer gif Contact Us
spacer gif
spacer gif
spacer gif
Help
spacer gif
spacer gif Zeitgeist
Support
FAQs
Tour
Feedback
Our Network

MBA B School Blog

MBA Buy Entrance Exam Forms

MBA BMS Blog

MBA MBA Blog

MBA BMM Network

Follow
       
   

 

Copyright 2004 - 2019 Management Paradise.